How to Get Provigil (Modafinil) in Maryland

What Provigil and modafinil actually are

Provigil is the original brand name for modafinil, a wakefulness-promoting medication classified as Schedule IV under the federal Controlled Substances Act. The FDA approved it for excessive daytime sleepiness associated with narcolepsy, and later added indications for shift-work sleep disorder and as an adjunct to CPAP therapy in obstructive sleep apnea when residual sleepiness persists (FDA label). Generic modafinil, sold under multiple manufacturer names, has been widely available since the brand's patent protection lapsed. Armodafinil (Nuvigil) is a related but separate drug and should not be confused with modafinil when comparing prices, coverage, or dosing.

Provigil is the brand name for modafinil, an FDA-approved Schedule IV medication for narcolepsy, shift-work disorder, and CPAP-refractory sleepiness in obstructive sleep apnea. In Maryland, any physician, nurse practitioner, or physician assistant with an active DEA registration can prescribe it after an in-person or telehealth evaluation. Insurer-specific rules for prior authorization, appeal rights, and out-of-pocket cost change over time and are not established facts that hold indefinitely; verify them with your plan and pharmacy before you rely on them.

What is established, what is plausible, and what needs verification

Some facts about modafinil access are stable and unlikely to change quickly. Others depend on a specific insurer, a specific pharmacy, or a specific point in time, and should not be treated as fixed.

Established and stable:

• Modafinil is Schedule IV and requires a prescription from a licensed provider with an active DEA registration.
• The FDA-approved indications are narcolepsy, obstructive sleep apnea (as an adjunct, not a replacement for CPAP), and shift-work disorder.
• Federal law generally allows up to five refills within six months for Schedule III-V prescriptions, though your specific prescriber and pharmacy can confirm how this applies to your prescription.
• The FDA label describes a drug interaction with hormonal contraceptives and a rare but serious risk of severe skin reactions, including Stevens-Johnson syndrome.

Plausible but not something this article can confirm for your situation:

• That a particular Maryland telehealth platform, insurer, or pharmacy will process your prescription within a specific number of days.
• That your specific insurer's prior authorization criteria match what is described here; PA criteria are set by each plan and change without notice.
• Any specific cash price or copay figure, since retail modafinil pricing varies by pharmacy, manufacturer, and discount program and shifts over time.

Not established from the evidence available for this page:

• Any claim that a named Maryland telehealth service, pharmacy chain, or discount program offers a particular turnaround time or price. No first-party data supports specific numbers here, so none are given.

Who can prescribe modafinil in Maryland

MDs, DOs, nurse practitioners, and physician assistants are all permitted to write modafinil prescriptions when they maintain an active state license and valid DEA registration. However, nurse practitioner practice authority and physician assistant supervision requirements differ across states and are periodically revised by state regulatory boards. Before scheduling an appointment with an NP or PA to obtain modafinil, verify the current requirements under Maryland Board of Nursing or Maryland Board of Physicians guidelines, as state-level prescribing rules of this type may be updated after this page is published.

Sleep medicine specialists and neurologists most commonly manage narcolepsy prescriptions. Primary care clinicians frequently prescribe modafinil for shift-work disorder or as an OSA adjunct after CPAP has been tried.

Telehealth prescribing for a controlled substance

Video telehealth visits for controlled-substance prescribing are broadly permitted across most states following changes to federal DEA telehealth policy in recent years, but the specific requirements, including whether an initial visit must include real-time video, whether audio-only follow-ups are acceptable, and whether an in-state license is required, are subject to state-level rules and periodic federal rule changes. Confirm the current requirement directly with a Maryland-licensed telehealth provider or the Maryland Board of Physicians before assuming a particular pathway is available, since telehealth controlled-substance policy has changed more than once in recent years and an outdated assumption here would be a genuine risk to a reader trying to get a prescription filled.

What a prescriber typically wants to see before prescribing

No single blood test is required before a modafinil prescription. In general clinical practice for these indications:

• Narcolepsy is diagnosed with an overnight polysomnogram followed by a multiple sleep latency test. Insurers commonly ask for this documentation before authorizing coverage.
• Shift-work disorder is usually diagnosed from clinical history describing a rotating or night-shift schedule with associated sleepiness or insomnia; formal sleep testing is not always required, though supporting documentation such as a sleep diary can strengthen an insurance appeal.
• OSA with residual sleepiness on CPAP typically requires documentation of CPAP adherence and continued Epworth Sleepiness Scale elevation despite adequate therapy.

Because modafinil is hepatically metabolized, some prescribers check baseline liver enzymes, and some check thyroid function to rule out other causes of fatigue before attributing symptoms to a primary sleep disorder. These are matters of clinical judgment for your prescriber, not a fixed checklist that applies to everyone.

Insurance coverage and prior authorization

Most commercial insurers and Medicaid managed care plans cover generic modafinil for the FDA-approved indications once prior authorization criteria are met; brand-name Provigil is rarely covered given generic availability. Typical prior authorization requests ask for a confirmed diagnosis, supporting sleep study or CPAP adherence data, and documentation that non-drug measures were tried or are not appropriate.

Specific turnaround times for prior authorization decisions, and specific appeal rights and deadlines, are set by state insurance regulation and by each plan's policy. These details change and are exactly the kind of fact a reader should verify with the Maryland Insurance Administration or their plan directly rather than take from a general reference page, since an outdated timeline stated with false confidence could cause a reader to miss an appeal deadline.

Off-label use, discussed further below, is far less likely to be covered, and many plans deny it outright absent a formal exception request.

Cost

Retail cash price and insured copay for generic modafinil vary by pharmacy, manufacturer, insurance tier, and discount program, and change over time. This page does not provide specific price figures because no verified, current, Maryland-specific pricing data was available to support them. Checking a current price comparison tool or calling your pharmacy directly will give you a more reliable number than any fixed figure printed here.

Verification checklist: stable facts versus facts you must check yourself

Use this checklist to separate what you can rely on long-term from what needs a fresh check before you act on it.

Stable facts (federal law and FDA label, unlikely to change quickly)

• Modafinil is Schedule IV; a valid prescription from a DEA-registered prescriber is required.
• FDA-approved indications: narcolepsy, OSA adjunct after CPAP, shift-work disorder.
• The FDA label lists a drug interaction between modafinil and hormonal contraceptives.
• The FDA label carries a warning about rare serious skin reactions, including Stevens-Johnson syndrome.
• Federal rules generally allow a defined number of refills within six months for Schedule III-V prescriptions; your pharmacist can confirm the exact count that applies to your prescription.

Facts that change and must be reverified at the time you need them

• Whether your specific Maryland insurer requires prior authorization for modafinil, and its current criteria.
• Current prior authorization and appeal turnaround times under Maryland insurance regulation.
• Whether Maryland Medicaid or your commercial plan covers off-label use, and under what exception process.
• Current telehealth prescribing rules for controlled substances applicable in Maryland (video requirement, audio-only follow-up allowance, DEA special registration status).
• Cash price and copay at your specific pharmacy, since these shift with manufacturer pricing and discount programs.
• Whether a specific pharmacy currently has modafinil in stock; the FDA Drug Shortage Database tracks ongoing national shortages and is worth checking directly (FDA Drug Shortage Database).

Do not accept without checking the source yourself

• Any specific number of days for insurer prior authorization decisions quoted on a general reference page.
• Any specific dollar price for 30-day or 90-day supplies quoted on a general reference page.
• Any claim that a named telehealth company or pharmacy chain has a particular Maryland-specific policy.

Compounded modafinil

Licensed 503A compounding pharmacies can prepare non-standard doses of modafinil, such as strengths not commercially manufactured, against a valid patient-specific prescription. Compounding a dose or form that duplicates a commercially available product is generally restricted under FDA guidance on the boundaries of traditional compounding. If a prescriber suggests a compounded dose, ask why a commercially available strength was not chosen first.

Filling and transferring a prescription

Once a prescriber sends an electronic prescription, you can fill it at any licensed pharmacy. Bring valid photo identification, since pharmacies verify identity for controlled-substance dispensing. If prior authorization is pending, you may need to pay cash and seek reimbursement later, or wait for approval.

If you are relocating to Maryland with an existing modafinil prescription, federal law generally allows one transfer of a Schedule IV prescription between pharmacies; a prescription that has already been transferred once cannot be transferred again. For ongoing care, the more durable solution is establishing care with a Maryland-licensed prescriber who can write new prescriptions, especially if you can bring prior sleep study documentation so testing is not unnecessarily repeated.

Safety monitoring and drug interactions

The FDA label lists headache, nausea, and nervousness among the more common adverse effects reported in clinical trials, and carries a warning about rare but serious skin reactions (FDA label). Modafinil induces certain liver enzymes and reduces the effectiveness of hormonal contraceptives; the label recommends backup contraception during treatment and for a period after stopping, and this is a genuinely important safety point for anyone using hormonal birth control. If you develop a new rash while taking modafinil, this warrants prompt medical evaluation rather than waiting for a routine follow-up.

Routine follow-up commonly includes review of side effects, sleepiness symptoms, and, for some patients, periodic blood pressure checks, since modafinil can modestly raise blood pressure in some individuals. The frequency of follow-up is a clinical decision between you and your prescriber.

Off-label use

Prescribers sometimes use modafinil off-label for fatigue related to multiple sclerosis, ADHD, or depression, and cognitive-enhancement use in people without a diagnosed sleep disorder. Evidence for cognitive-enhancement use in healthy people is limited and inconsistent, and this use is not an FDA-approved indication; insurance coverage for it is inconsistent and often requires a formal exception request. A broader systematic review of pharmacological approaches to cognition, including stimulant-class agents, in bipolar disorder illustrates how mixed and population-specific this evidence base is even in patients with a diagnosed condition, and its findings should not be generalized to unrelated populations without checking the paper directly (systematic review, bipolar disorder cognition).

Modafinil has also been studied as an investigational pharmacotherapy for stimulant use disorder and cocaine use disorder, an off-label research use distinct from its approved indications. A 2026 meta-analysis of pharmacotherapy trials for stimulant use disorder examined reduced-use and abstinence outcomes across twelve randomized controlled trials, and a separate 2025 analysis looked at craving and use trajectories during cocaine use disorder pharmacotherapy trials (stimulant use disorder meta-analysis; cocaine craving trajectory analysis). These are trial-level and meta-analytic findings about an off-label research use, not an FDA-approved indication, and readers considering this use should discuss it with a prescriber and review the primary papers rather than rely on a summary here.

When urgent care is appropriate

Seek urgent medical attention for a new rash, blistering, or skin peeling while on modafinil, for chest pain, irregular heartbeat, or severe agitation, or for any allergic reaction such as swelling of the face or throat. These are not routine side effects to manage by waiting for the next scheduled visit.